SHR-1701 in Combination With Famitinib in Patients With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05979961` - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma	Phase 3
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Recruiting	`NCT06055816` - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma	Phase 2
Recruiting	`NCT05547971` - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting	`NCT04547088` - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma	Phase 2
Not yet recruiting	`NCT04548271` - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma	Phase 2
Recruiting	`NCT02795169` - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma	Phase 1/Phase 2
Terminated	`NCT02801487` - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma	Phase 1/Phase 2
Terminated	`NCT02569788` - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma	Phase 1/Phase 2
Completed	`NCT02237924` - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma	Phase 2
Recruiting	`NCT02044562` - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients	N/A
Terminated	`NCT01694576` - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation	Phase 2
Recruiting	`NCT01462903` - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors	Phase 1
Completed	`NCT01271439` - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma	Phase 2
Completed	`NCT00535795` - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA	Phase 3
Completed	`NCT00379262` - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma	Phase 3
Completed	`NCT03398980` - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy	N/A
Completed	`NCT01309633` - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)	Phase 2
Not yet recruiting	`NCT05519956` - Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines	Phase 3

NCT number	NCT05020925
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Qing Yang, MD
Phone	+86-021-15705155017
Email	qing.yang@hengrui.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	September 2021
Completion date	February 2024

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms